Researchers from Zhengzhou University have reported the discovery of lysine-specific histone demethylase 1A (LSD1) inhibitors as potential immune response enhancers for the treatment of gastric cancer.
The calcineurin inhibitor tacrolimus is an immunosuppressive drug frequently used to prevent transplant rejection in solid organ transplant patients. Tacrolimus acts by suppressing T-cell activity within and around the transplanted organ. However, this drug also inhibits T-cell function in the skin, contributing to a high incidence of skin cancer among transplant recipients.
In a positive sign for its future success, Harbinger Health Inc. closed a $140 million series B fundraising round, bringing total funds raised since its founding in 2020 to $190 million. The new funds will be used to support completion of the company’s CORE-HH 10,000 participant study of its blood-based multicancer early detection (MCED) test. The company expects to complete enrollment in CORE-HH, a three-part case control, adaptive study with development, validation and longitudinal cohorts in 2024.
Flare Therapeutics Inc. has patented peroxisome proliferator-activated receptor γ (PPARγ, PPARG) inverse agonists reported to be useful for the treatment of bladder cancer.
Researchers at Firefly Bio Inc. have prepared antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting HER2 covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, inflammation and infections.
Researchers from Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. and affiliated organizations have published preclinical data for the novel rearranged during transfection (RET) kinase inhibitor, FHND-5071.
Reninomas are rare renin-secreting kidney tumors, resulting from a neoplastic expansion of juxtaglomerular cells of the kidney, which are cells that regulate blood pressure via the secretion of renin. Based on previous research that has proposed a central role for NOTCH1 signaling in the regulation of renin secretion by juxtaglomerular cells, researchers from Wellcome Sanger Institute, University of Cambridge, and affiliated organizations aimed to investigate the role of NOTCH1 in reninoma.
Mission Bio Inc. released its Tapestri single-cell minimal residual disease (MRD) assay for acute myeloid leukemia (AML) on September 26, with the goal of enabling greater personalization of care for patients with blood cancers. The test can provide insights into the progression of AML and help identify targets for treatment in addition to identifying patients truly experiencing relapse as distinct from having pre-leukemic or precursor clones.
Several Insilico Medicine Inc. patents describe diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer and viral infection.
Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have jointly described new phosphatidylinositol 3-kinase (PI3K) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
RSS
